CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Oxford BioMedica plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Oxford BioMedica plc
Windrush Court,Transport Way
Phone: +44 1865783000p:+44 1865783000 OXFORD, OX4 6LT  United Kingdom Ticker: OXBOXB
Business Summary
Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. It provides viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers several technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. It has bioprocessing and manufacturing facilities across Oxfordshire, United Kingdom, Lyon and Strasbourg, France and near Boston, MA, United Sates. Its Platform segment is involved in bioprocessing and process development activities undertaken for third parties. Its Viral Vector includes LentiVector platform, inAAVate platform, and Other Viral Vectors. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
8741 Management services
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Non-Executive Chairman of the Board Roch F.Doliveux 65 3/27/2023 6/24/2020
Chief Executive Officer, Executive Director FrankMathias 62 3/27/2023 3/27/2023
Non-Executive Vice Chairman of the Board StuartHenderson 6/1/2025 6/1/2016
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ABL Europe S.A.S. 4 Rue Laurent Fries Illkirch-Graffenstaden France

Business Names
Business Name
ABL Biomanufacturing
ABL Europe S.A.S.
ABL, Inc.
5 additional Business Names available in full report.

General Information
Number of Employees: 834 (As of 6/30/2024)
Outstanding Shares: 105,923,083 (As of 10/31/2024)
Shareholders: 3,641
Stock Exchange: LON
Fax Number: +44 1865783001


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024